The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•27 February 2026•

1 min read

Puma Biotechnology Shares Plunge 14% Despite Q4 Beat on Weak 2026 Outlook

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

Key Facts

1Puma Biotechnology's Q4 earnings and sales beat estimates with a 28% jump in revenue.

Puma Biotechnology (PBYI) reported strong fourth-quarter financial results that exceeded analyst expectations for both earnings and revenue. The biotechnology firm saw its revenue surge by 28% year-over-year during the quarter, driven by solid operational performance. However, these positive quarterly results were overshadowed by a disappointing financial forecast for the year 2026. Consequently, the company's stock price plummeted by 14% in after-hours trading as investors reacted to the weak long-term guidance. The market's reaction underscores a significant shift in focus toward future growth sustainability over immediate quarterly gains. Analysts noted that the downward revision in future expectations outweighed the current momentum in sales growth.